NeuRA Magazine #26

Feature story


Professor Cyndi Shannon Weickert has been on a quest to determine the causes of schizophrenia for over 30 years. She has made a series of breakthrough discoveries that will have a global impact in the way we conceptualise the biological basis of this major mental illness.

Importantly, her recent work is poised to transform the treatment of those with schizophrenia. Her latest discovery has identified immune cells from the blood found at increased levels in the brains of a substantial subset of those with schizophrenia. These cells were not known to be in proximity to neurons and the identification of these culprit cells suggest they may play a role in disease development or decline associated with schizophrenia that was never previously considered.

The discovery will transform global schizophrenia research and open new avenues for developing targeted therapies.

Professor Shannon Weickert says researchers have long thought there were three main cellular types that could contribute to the mystery of what caused schizophrenia with the primary pathology residing in the neuron, the glia, or even the endothelial cells. Her research at NeuRA has identified a fourth player – the macrophage, a type of white blood cell, which was seen in the brain tissue of people with schizophrenia who had high levels of inflammation.

“What we believe is the glial cells are ‘angry’ and are emitting distress signals and changing the surface of the endothelial cells so that these can catch and reel in monocytes, a type of white blood cell, from the bloodstream and into the brain tissue,” says Professor Shannon Weickert.

These monocytes then transform into macrophages once inside the human brain. The macrophage, which means ‘big eaters’ in Greek, can be thought to be good as these cells digest cellular debris and microbes. However, these cells have a dark side as they can destroy healthy tissue when they go rogue.

“Through the microscope I saw massive amounts of these clusters of small brown-coloured cells packed along the blood vessels in the brain tissue, close to the neurons,” Professor Shannon Weickert says.

“Before we thought it was primarily the cells that resided in the brain that were causing schizophrenia and for over a century people have been focusing on neurons and glial cells, but we’re the first to show these immune cells are in the brain, in proximity to the neurons and positioned to do damage.”

The presence of immune cells in the brain tissue can produce inflammatory factors to further drive the neuronal damage in schizophrenia. Immune cells would only enter the brain to conduct immune surveillance, then may die out or re-enter the bloodstream. In schizophrenia, they may over-react and cause collateral damage.

Professor Shannon Weickert said these findings suggest schizophrenia researchers should be working with immunologists to develop treatments which target the immune system.

One in every 100 Australians lives with schizophrenia. No single cause for schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress these symptoms and do not target the cause of the disorder. These drugs only partially relieve symptoms and can produce unwanted side-effects.

“This opens whole new avenues for therapy. We may be able to find a way to block entry of these immune cells into the brain to see if that’s going to seriously thwart symptoms and improve brain function for people with schizophrenia,” says Professor Shannon Weickert. The inflammation observed in 40 per cent of the study sample, indicates future therapies could benefit a large portion of the community.

See what’s going on at NeuRA


Cortical activity during balance tasks in ageing and clinical groups using functional near-infrared spectroscopy

Prof Stephen Lord, Dr Jasmine Menant Walking is not automatic and requires attention and brain processing to maintain balance and prevent falling over. Brain structure and function deteriorate with ageing and neurodegenerative disorders, in turn impacting both cognitive and motor functions.   This series of studies will investigate: How do age and/or disease- associated declines in cognitive functions affect balance control? How is this further impacted by psychological, physiological and medical factors (eg. fear, pain, medications)? How does the brain control these balance tasks?     Approach The experiments involve experimental paradigms that challenge cognitive functions of interest (eg.visuo-spatial working memory, inhibitory function). I use functional near-infrared spectroscopy to study activation in superficial cortical regions of interest (eg. prefrontal cortex, supplementary motor area…). The studies involve young and older people as well as clinical groups (eg.Parkinson’s disease).   Studies Cortical activity during stepping and gait adaptability tasks Effects of age, posture and task condition on cortical activity during reaction time tasks Influence of balance challenge and concern about falling on brain activity during walking Influence of lower limb pain/discomfort on brain activity during stepping   This research will greatly improve our understanding of the interactions between brain capacity, functions and balance control across ageing and diseases, psychological, physiological and medical factors, allows to identify targets for rehabilitation. It will also help identifying whether exercise-based interventions improve neural efficiency for enhanced balance control.